html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

PapersPMID:25057276

Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial.

Evidence-based complementary and alternative medicine2014The record ↗

findings: 2
compound: 1
endpoints: 2

pterostilbene

lowersDiastolic blood pressure
lowersSystolic blood pressure

Study, every finding: RCT
Dose studied, every finding: pterostilbene 125 mg orally twice daily
Population, every finding: Adults with hypercholesterolemia; high-dose arm only (pterostilbene 125 mg twice daily) against matching placebo, 6-8 weeks

What moved

How to read these marks →

“There was a significant reduction versus placebo in SBP and DBP with high dose pterostilbene (see Figure 2).”
- Decreases diastolic blood pressure
  moderate
  Interests
  Industry funded
- Decreases systolic blood pressure
  moderate
  Interests
  Industry funded

Study record

Design: randomised controlled trial
Species: human
Population: Patients with hypercholesterolemia (baseline total cholesterol >=200 mg/dL and/or LDL >=100 mg/dL)
Participants: 80
Comparator: placebo
Duration: 52 days
Endpoints measured: 23